News | May 11, 2022
Bayer posts higher sales, profit in first quarter
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The plan is to advance innovative therapies to drug-resistant cancers
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Avacc 3 has significant advantages over existing whooping cough vaccines
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Subscribe To Our Newsletter & Stay Updated
